Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
Zepbound , the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Lilly's Taltz and Zepbound used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
Lilly's Retevmo delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Lilly's Retevmo delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
